Ojetti V, Petruzziello C, Migneco A, Gnarra M, Gasbarrini A, Franceschi F
Department of Medical Sciences, Division of Gastroenterology, Catholic University of the Sacred Heart, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2017 Apr;21(7):1702-1708.
Constipation is a common symptom affecting up to 30% of the Western population and is strongly associated with the presence of intestinal methanogens, which may directly inhibit motor activity. Two recent studies performed on adult and children affected by chronic constipation showed that the supplementation with L. reuteri significantly improved bowel movements. Whether its action is related to a decreasing of methane (CH4) production has never been tested. We have therefore designed a study aimed at testing this hypothesis.
Data of 20 adults (12 females, mean age 36.2 ± 13.7) affected by functional constipation, treated with the probiotic L. reuteri (DSM 17938) for 4 weeks who performed a H2/CH4 lactulose breath test (LBT) in our institution showing a CH4 production higher than 5 ppm were retrospectively analyzed from March to June 2015. Data recorded in their stool diary, reporting the frequency of defecations and stool consistency were also analysed, as well as the result of the LBT performed at the end of the treatment with L. reuteri.
Four weeks of L. reuteri administration was associated with a significant decrease of mean CH4 production determined by LBT (from 20.8 ± 15 to 8.9 ± 8.6; p < 0.0001 CI 95%) and of AUC value (from 5101.5 ± 3571.13 to 2128.4 ± 2110.8; p < 0.0001 CI 95%). Moreover, a total disappearance of CH4 production (< 5 ppm at LBT) was observed in 11 patients, while, we did not observe any significant decrease of H2 production (from 13.2 ± 8.8 to 11.4 ± 7.3, CI 95%, n.s.).
This study highlights for the first time the beneficial effect of Lactobacillus reuteri (DSM 17938) on chronic constipation, via a significant decrease of CH4 production.
便秘是一种常见症状,影响着高达30%的西方人群,且与肠道产甲烷菌的存在密切相关,产甲烷菌可能直接抑制运动活性。最近两项针对慢性便秘成人和儿童的研究表明,补充罗伊氏乳杆菌可显著改善排便情况。但其作用是否与甲烷(CH4)生成减少有关尚未得到验证。因此,我们设计了一项研究来验证这一假设。
回顾性分析了2015年3月至6月在我院接受治疗的20名功能性便秘成人患者(12名女性,平均年龄36.2±13.7岁)的数据,这些患者接受了罗伊氏乳杆菌(DSM 17938)治疗4周,并进行了氢/甲烷乳果糖呼气试验(LBT),结果显示甲烷生成量高于5 ppm。分析了他们在粪便日记中记录的数据,包括排便频率和粪便稠度,以及罗伊氏乳杆菌治疗结束时进行的LBT结果。
服用罗伊氏乳杆菌4周后,LBT测定的平均甲烷生成量显著降低(从20.8±15降至8.9±8.6;p<0.0001,95%置信区间),AUC值也显著降低(从5101.5±3571.13降至2128.4±2110.8;p<0.0001,95%置信区间)。此外,11名患者的甲烷生成完全消失(LBT时<5 ppm),而我们未观察到氢气生成有任何显著降低(从13.2±8.8降至11.4±7.3,95%置信区间,无显著性差异)。
本研究首次强调了罗伊氏乳杆菌(DSM 17938)通过显著降低甲烷生成量对慢性便秘具有有益作用。